Indication
Primary CNS Lymphoma
6 clinical trials
6 products
1 drug
Clinical trial
An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System LymphomaStatus: Recruiting, Estimated PCD: 2026-08-01
Product
ibrutinibProduct
EmavusertibClinical trial
Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary Central Nervous System (CNS) LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
CD19CAR T-cellsClinical trial
Pilot Study of Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS LymphomaStatus: Recruiting, Estimated PCD: 2025-03-31
Product
Hyperpolarized pyruvateClinical trial
Pilot Study of Tisagenlecleucel, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, in Patients With Primary Central Nervous System LymphomaStatus: Active (not recruiting), Estimated PCD: 2021-12-11
Drug
TisagenlecleucelClinical trial
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)Status: Recruiting, Estimated PCD: 2027-03-31
Product
TirabrutinibClinical trial
Phase II Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With Primary CNS Diffuse Large B-cell Lymphoma (Nickname: Lemon-C Study)Status: Recruiting, Estimated PCD: 2024-11-02
Product
Rituximab